ReShape Lifesciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 31
- Market Cap
- -
- Introduction
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.
ReShape Lifesciences Announces Merger with Vyome and Asset Sale to Biorad Amid Q1 2025 Financial Results
• ReShape Lifesciences reported Q1 2025 financial results showing revenue of $1.1 million, a 42.7% decrease from the same period in 2024, primarily due to competition from GLP-1 pharmaceutical weight-loss alternatives.
• The company is progressing toward finalizing its merger with Vyome Therapeutics and asset sale to Biorad Medisys, with the S-4 recently declared effective and plans to set a record date in the near future.
• ReShape strengthened its intellectual property portfolio with multiple patent allowances for its Diabetes Neuromodulation system and intragastric balloon technology, extending protection through at least 2039.
ReShape Lifesciences' Diabetes Neuromodulation Device Shows Promise in Preclinical Studies
• ReShape Lifesciences presented preclinical data demonstrating their proprietary Diabetes Neuromodulation device can effectively reverse insulin-induced hypoglycemia without cardiac side effects in a swine model of Type 1 diabetes.
• The technology utilizes targeted stimulation of the sub-diaphragmatic posterior vagus nerve to rapidly increase blood glucose levels during hypoglycemic episodes, offering a potential alternative to conventional treatments.
• ReShape recently received a Notice of Allowance from the USPTO for a patent related to this technology, providing protection until April 2039 and strengthening their intellectual property portfolio of 62 issued or pending patents.
Vyome's VT-1953 Shows Promise in Phase 2 Trial for Malignant Fungating Wound Treatment
Vyome Therapeutics has reported positive interim results from a Phase 2 study of VT-1953 topical gel in treating malignant fungating wounds (MFW). The treatment demonstrated significant reduction in malodor and pain, with patients showing 75% reduction in malodor and 50% reduction in lesion pain after 14 days of treatment. Based on these encouraging results, the company plans to initiate pivotal studies in 2025.
© Copyright 2025. All Rights Reserved by MedPath